Data as of Q4 2025 (Dec 31, 2025)

Vestal Point Capital, LP

โ€ขCIK: 1974915โ€ขFiling: Q4 2025

**Vestal Point Capital, LP** manages $2.9B across a diversified portfolio of 76 positions. The fund exhibits significant concentration in technology and specialized sectors, highlighted by top holdings including ABVX at $256.2M and NDQ at $215.0M. Further notable allocations include ACLX ($190.7M) and TERN ($181.8M). This structure suggests a focused, high-conviction approach within select market segments.

Total AUM
$2.7B
+ $215.0M in options
QoQ Performance
+23.7%
Positions
75
+ 1 option
Top 10 Concentration
50.2%
Latest Filing
Q4 2025

Top Holdings Allocation

ABVX
NDQ
ACLX
TERN
BMRN
ABVX8.7%
NDQ7.3%
ACLX6.5%
TERN6.2%
BMRN6.1%
GMED3.8%
NRIX3.0%
ALC3.0%

๐Ÿ“ˆ Biggest Buys

NDQPUT
Invesco QQQ Trust Series 1
NEW
7.3% of portfolio
TERN
Terns Pharmaceuticals Inc
NEW
6.2% of portfolio
BMRN
BioMarin Pharmaceutical Inc
+261.4%
6.1% of portfolio
ABVX
Abivax SA
+90.0%
8.7% of portfolio
ACLX
Arcellx Inc
+134.0%
6.5% of portfolio

๐Ÿ“‰ Biggest Sells

NUVL
Nuvalent Inc
-95.8%
0.2% of portfolio
ASND
Ascendis Pharma A/S
-70.8%
1.3% of portfolio
RGEN
Repligen Corp
-79.2%
0.5% of portfolio
DYN
Dyne Therapeutics Inc
-95.7%
0.1% of portfolio
JAZZ
Jazz Pharmaceuticals PLC
-42.0%
1.7% of portfolio

Sector Breakdown

Other94.0%
Healthcare6.0%

๐Ÿšช Exited Positionssold since Q3 2025

AM6
Amicus Therapeutics Inc
SOLD
$76.8M
ISI
Ionis Pharmaceuticals Inc
SOLD
$70.3M
BDX
Becton Dickinson & Co
SOLD
$60.8M
DNTH
Dianthus Therapeutics Inc
SOLD
$46.4M
CYTK
Cytokinetics Inc
SOLD
$39.8M
+25 more exited positions

Changes from Q3 2025

NEW25 new positions
โ†‘24 increased
โ†“20 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023